Conduction block in the forearm associated with acute varicella zoster virus infection

We report the case of an adult patient with neurophysiological evidence of persisting conduction block in the forearm segment of the left median nerve and absent responses from the sensory branch of the musculocutaneous nerve (MCN), which had developed during an episode of acute generalised varicella zoster virus (VZV) infection. Clinical manifestations of motor involvement in herpes zoster (HZ) are generally rare and usually due to central nervous system involvement. Motor peripheral nervous system manifestations do exist and have been ascribed to nerve root degeneration due to lymphocytic inflammation and vasculitis with possible spread into the spinal cord. Recently, conduction block has been identified for the first time as the cause of weakness in an immunocompromised patient with HZ, with evidence of extension of VZV infection along the median nerve on magnetic resonance imaging, but persisting conduction block has up to now not been described as a complication of acute VZV infection.

Case report

A 29 year old Caucasian electrician was seen for neurophysiological assessment with weakness of his left hand and numbness along the lateral aspect of his left forearm of 9 months’ duration. The numbness had developed 9 days into a severe primary attack of chickenpox, which required hospitalisation. The weakness remained unnoticed by the patient until detection during routine follow up. Oral aciclovir had been commenced 3 days after the onset of the acute illness. No intravenous access had been used in the patient’s left arm. The past medical history included an anecdotal first primary attack of chickenpox at the age of 4, but was otherwise unremarkable.

Findings on neurological examination were confined to the left arm. There was no muscle wasting or fasciculations and deep tendon reflexes were preserved. Muscle testing revealed weakness in the left hand corresponding to median innervated muscles: abductor pollicis brevis (APB) (4/5), opponens pollicis (4/5), and first and second lumbricals (4/5) (MRC rating scale). In addition, there was hypeaesthesia for light touch and pinprick in the territory of the sensory branch of MCN.

Magnetic resonance imaging of both forearms was inconclusive with no evidence of significant signal alteration at the proposed site of the conduction block.

Motor nerve conduction studies revealed partial conduction block in the left median nerve between 9.1 and 11.1 cm above the proximal wrist crease (fig 1) with a reduced forearm velocity (34.6 m/s) and absent F-waves. The elbow mixed median nerve potential was smaller on the left than on the right (15.2 v 33.9 μV), thus confirming the presence of a partial conduction block in the forearm segment of the left median nerve. The sensory nerve action potential for the left sensory branch of MCN was absent with normal amplitudes and velocities from the right. Nerve conduction studies were normal for the right median as well as the ulnar and radial nerves bilaterally. Needle electromyography showed normal motor units with a reduced interference pattern and single fasciculation potentials in left APB and was normal in left first dorsal interosseous, flexor pollicis longus, biceps, and extensor digitorum communis.

Comment

Conduction block in acute VZV infection has, to the best of our knowledge, never been described before. Partial infarction of a mixed nerve in vasculitic mononeuritis multiplex can cause conduction block by selectively damaging Schwann cells, although axonotmesis with axonal damage and sensory-motor symptoms in the affected nerve would be more typical and should have been apparent during neurophysiological testing. Both the median nerve and the sensory branch of MCN share fibre supply from cervical nerve roots which later form the lateral cord, and they are often in close anatomical proximity in the arm due to frequent anatomical variations. The simultaneous involvement of the median nerve and the sensory branch of MCN might thus indicate a direct spread of the virus between the two nerves. Alternatively, indirect spread from the purely sensory branch of MCN via the spinal cord might have occurred. Autopsies of nervous tissue from HZ patients have shown VZV DNA and antigen to be present in damaged nerve fibres including motor neurons, suggestive of neuronal spread. Recently, conduction block in the forearm segment of the median nerve in a case of HZ has speculatively been attributed to local damage of Schwann cells of the motor nerves by direct local invasion or remote allergic mechanisms, although the exact pathophysiology in these cases remains to be established.

The patient was found to have fasciculation potentials but no other forms of spontaneous activity in APB, but in none of the other muscles tested. The observed fasciculation potentials most likely represent axonal hyperexcitability at the site of the conduction block in analogy to the presumed mechanism responsible for the occurrence of single and grouped fasciculation potentials in other neuropathies characterised by persistent conduction block.

U S Raasch, J P Heath
Department of Clinical Neurophysiology, University Hospital of Wales, Cardiff, UK
Correspondence to: Dr U S Raasch, Department of Clinical Neurophysiology, University Hospital of Wales, Cardiff, UK; raasch@ Cardiff.ac.uk

Written confirmation from the Local Research and Ethics Committee in Cardiff was obtained confirming that formal ethical approval was not needed for this case study.

doi: 10.1136/jnnp.2004.059147

Competing interests: none declared

References

Toscan virus causing severe meningoencephalitis in an elderly traveller

Toscan virus (TOSV) is classified in the sandfly fever virus group of arboviruses (family Bunyaviridae, genus Phlebovirus) along with Sicilian (SFSV) and Neapolitan (SFNV) sandfly fever virus. SFSV and SFNV cause a transient febrile illness, whereas TOSV also causes mild acute aseptic meningitis. In endemic regions TOSV has been identified as an important cause of viral aseptic meningitis. Previously, severe TOSV meningitis has been described only occasionally. Within three to six days after infection symptoms such as fever, myalgia, headache, vomiting, and neck rigidity do occur, but a lesser degree of encephalitis involvement has generally been reported. As in other viral meningitides, symptoms of aseptic meningitis related to TOSV infection disappear completely within a few days. Asymptomatic infections and infections without CNS involvement also occur.

The brain involvement in this case caused a severe, long lasting impairment of consciousness, seizures as an unusual clinical manifestation, and a prolonged convalescence period. Seldom reported before, raised liver enzymes can be interpreted as a sign of a systemic infection with involvement of the liver.

Table 1: Results of cerebrospinal fluid and serum sample analysis after admission (as far as we know this is the first time that markers of cell damage and immune reaction have been measured in a patient with acute tosca virus meningoenecphalitis)

<table>
<thead>
<tr>
<th>Reference range</th>
<th>Day 2</th>
<th>Day 6</th>
<th>Day 13</th>
<th>Day 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC count (cells/mm$^3$)</td>
<td>0 to 5</td>
<td>265</td>
<td>30</td>
<td>16</td>
</tr>
<tr>
<td>Lactate (mM/l)</td>
<td>1.1 to 2.2</td>
<td>4.3</td>
<td>2.5</td>
<td>2.2</td>
</tr>
<tr>
<td>Glucose (mM/l)</td>
<td>2.78 to 4.16</td>
<td>7.33</td>
<td>4.88</td>
<td>4.50</td>
</tr>
<tr>
<td>Total protein (mg/dl)</td>
<td>15-45</td>
<td>47</td>
<td>25</td>
<td>28</td>
</tr>
<tr>
<td>Oligodendroglial binding</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Tau protein (pg/ml)</td>
<td>&lt;350</td>
<td>194</td>
<td>191</td>
<td>332</td>
</tr>
<tr>
<td>(12-Microglobulin) mg/mL</td>
<td>&lt;2</td>
<td>NA</td>
<td>5.2</td>
<td>3.1</td>
</tr>
<tr>
<td>Neurone specific enolase</td>
<td>&lt;12.5</td>
<td>8.2</td>
<td>7.3</td>
<td>7.1</td>
</tr>
<tr>
<td>S100 protein (mg/ml)</td>
<td>&lt;2300</td>
<td>NA</td>
<td>1030</td>
<td>644</td>
</tr>
<tr>
<td>Anti-TOSV antibodies in CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG IFA</td>
<td>&lt;1:10</td>
<td>1:20</td>
<td>1:2560</td>
<td>1:5120</td>
</tr>
<tr>
<td>IgM IFA</td>
<td>&lt;1:10</td>
<td>&lt;1:10</td>
<td>&lt;1:10</td>
<td>&lt;1:10</td>
</tr>
<tr>
<td>IgG EIA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgM EIA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anti-TOSV antibodies in serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG IFA</td>
<td>&lt;1:10</td>
<td>1:640</td>
<td>1:5120</td>
<td>1:10240</td>
</tr>
<tr>
<td>IgM IFA</td>
<td>&lt;1:10</td>
<td>1:80</td>
<td>1:160</td>
<td>1:160</td>
</tr>
<tr>
<td>IgG EIA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgM EIA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

CSF, cerebrospinal fluid; EIA, enzyme immunosorbent assay; IFA, immunofluorescence assay; NA, not assessed; WBC, white blood cell.
Owing to the large variety of pathogens causing acute aseptic meningitis, clinicians rely on rapid laboratory confirmation of suspected cases by standard methods such as RT-PCR or the plaque reduction neutralisation test (PRNT). Nowadays, PRNT is rarely used owing to its complexity and time consuming nature, while RT-PCR appears inadequate because of the short duration of the viraemia. Recently developed EIA formats can establish the presence of infection by detecting specific IgM in acute phase samples and were able to confirm TOSV infection in this case. With millions of travellers and increasing TOSV infections around the Mediterranean basin, commercially available EIA methods will be of growing importance. In addition to other severe travel related diseases, TOSV infections now need to be considered by physicians.

J Kuhn, H Bewermeyer, U Hartmann-Klosterkoetter
Department of Neurology, Kliniken der Stadt Köln, Krankenhaus Merheim, Cologne, Germany

P Emmerich, S Schilling
Bernhard Nocht Institute For Tropical Medicine, Department of Virology, Hamburg, Germany

M Valassina
University of Siena, Department of Molecular Biology, Microbiology Section, Laboratory of Virology, Siena, Italy

Correspondence to: Dr Jens Kuhn, Department of Neurology, Kliniken der Stadt Köln, Krankenhaus Merheim, Östmerheimerstrasse 200, 51109 Cologne, Germany; Kuhn@kliniken-koeln.de; JKuhn11@aol.com
doi: 10.1136/jnnp.2004.060863

References

Intracerebral haemorrhage in CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare hereditary disease characterised by recurrent transient ischaemic attacks, strokes, and vascular dementia. Pathological studies reveal multiple small infarcts and diffuse white matter changes as well as vascular alterations most prominent in small arteries. The presence of granular osmiophilic material in arterial walls on ultrastructural examination is pathognomonic. Mutations in the notch3 gene located on chromosome 19 are associated with the disease. Here we report a patient with an unusual clinical course with recurrent intracerebral haemorrhage.

Case report
A 47 year old woman was admitted after a fall at home, followed by several minutes of unconsciousness. Her past medical history was uneventful. In particular, there was no history of migraine or depression, and she was not taking any drugs. On admission, her husband reported memory deficits for several weeks. Initially, the patient complained about headaches and mild dysarthria. Moderate left sided hemiataxia and pronation of the left arm were present. Blood pressure was raised to 220/120 mm Hg.

Figure 1  Bleeding in the left cerebellar hemisphere as shown in pdr T2 tse (A) and T2* (D). White matter lesions in the FLAIR sequence (B, E): note the lesions in the external capsule which are often present in CADASIL (B). (C) Acute ischaemic lesions in the right hemisphere in a diffusion weighted image. (F) Multiple microbleeds shown in T2*. CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; FLAIR, fluid attenuated inversion recovery.
without a known history of arterial hypertension. Neuropsychological deficits were prominent in impaired semantic, visual-spatial, and episodic memory, and in deterioration in cognitive speed. Concentration and mathematical problem solving were also reduced, indicating severe cognitive impairment. Initial cranial computed tomography revealed a haemorrhage of 20 mm diameter in the left cerebellar hemisphere. Subsequent magnetic resonance imaging (MRI) with T2* gradient echo (GE) showed more than 25 small haemorrhages distributed over the entire brain. T2 weighted scans showed white matter lesions with periventricular emphasis (Fig 1). Serum markers for vasculitis and coagulation indices were normal, as was the cerebrospinal fluid. An ophthalmological examination showed hypertensive changes. Ultrasound sonography of the extracranial and intracranial vessels revealed arteriosclerotic vessel walls but no stenosis. Electronmicroscopic examination of a skin biopsy showed granular osmiophilic material (GOM) in the basal lamina of small arterioles, establishing the diagnosis of CADASIL. Direct bidirectional sequencing of all exons coding for epidermal growth factor (EGF)-like repeat domains (exons 2 to 24) of notch3 coding for epidermal growth factor (EGF)-like repeat domains (exons 2 to 24) of notch3 showed no mutations in notch3 gene. Another study found microbleeds in 31% of all CADASIL patients examined, and an increased risk of intracerebral haemorrhage was predicted. The presence of microbleeds correlated with age and the use of antiplatelet drugs. CADASIL leads to degeneration of small arterioles, thereby increasing the probability of vessel rupture in arterial hypertension. Although there was no relevant medical history and she was not taking any medication, blood tests, including erythrocyte sedimentation rate (ESR) and C reactive protein (CRP), were normal. Computed tomography scan of the brain and analysis of the cerebrospinal fluid (CSF) were normal. Gynaecological examination showed no retained products of conception. The seizures proved refractory to treatment with intravenous lorazepam. She was transferred to a specialist neurological centre that day. On arrival she was agitated, disoriented and pyrexic (38°C). Generalised tonic clonic seizures were continued. Neurological examination was normal except that all limb reflexes were pathologically brisk and plantar responses were extensor. General examination was unremarkable. Despite being given “loading” doses of phenytoin, phenobarbital and magnesium sulphate, the seizures continued. She was anaesthetised and intubated, and mechanical ventilation was introduced.

Catastrophic primary antiphospholipid syndrome: presenting as status epilepticus

Antiphospholipid syndrome (APS) is defined as the occurrence of arterial or venous thrombosis or recurrent miscarriage, with raised titres of antiphospholipid antibodies, namely lupus anticoagulant (LA) or antiphospholipid antibodies (aCL). An increased risk of intracerebral haemorrhage in patients with CADASIL in combination with arterial hypertension. While the white matter pathology in the patient may appear relatively sparse, lesions in the external capsule and the temporal lobe typical of CADASIL were present. We conclude that CADASIL should be considered in patients with cerebral haemorrhage, and careful blood pressure management is particularly important in CADASIL patients, as the risk of vessel rupture and subsequent intracerebral haemorrhage appears to be further increased compared with patients with arterial hypertension alone. While there is no effective treatment for CADASIL, control of arterial hypertension could at least slow the rate of deterioration in this disabling and dementing disorder.

References

Treatment with high dose intravenous aciclovir for presumed viral encephalitis was commenced.

Intravenous immunoglobulin had the best survival benefit; 1 = mild improvement; 2 = moderate improvement; 3 = good improvement; 4 = complete resolution; 5 = no improvement. The successful application of botulinum toxin (BTX) injections in the treatment of focal hand dystonia is largely dependent on careful evaluation and selection of muscles to be injected. It has been suggested that patients should be examined for abnormal postures at rest and while carrying out the affected task in question as well as other tasks (such as using a cup or a comb). Simple techniques such as the localisation of subjective pain and fatigue accompanied by palpation of the area of discomfort can also be used. Mirror dystonia consists of dystonic postures and movements of the dominant hand while writing or performing other tasks with the non-dominant hand. We present a series of six patients who were successfully injected with BTX using mirror dystonia as an additional tool for muscle evaluation.

We carried out a retrospective review of the case records of consecutive patients with writing dystonia (writ handwriting and/or writing tremor) who had been injected with BTX type A (Botox®, Allergan Pharmaceuticals, Irvine, California, USA) between November 2000 and October 2002 at our movement disorders clinic. Our study was limited to patients with writing dysfunction who displayed mirror dystonia while writing with their non-dominant hand. We specifically examined patients for mirror dystonia by asking them to write yok with their non-dominant hand while resting the dominant hand on the ulnar side of the forearm (unaware of our focus on the detection of mirror dystonia of the resting limb). Patients were injected under EMG guidance, using an Allergan® EMG needle. We recorded the muscles injected and the dose each muscle received. Peak effect was defined as the maximum benefit obtained from the injection. It was rated on a 0 to 3 global impression scale (0 = no effect; 1 = mild improvement; 2 = moderate improvement; 3 = marked improvement). The presence and severity of adverse events was also recorded. We also looked at the concordance between observation of the dominant limb in the action of writing and

Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction

The successful application of botulinum toxin (BTX) injections in the treatment of focal hand dystonia is largely dependent on careful evaluation and selection of muscles to be injected. It has been suggested that patients should be examined for abnormal postures at rest and while carrying out the affected task in question as well as other tasks (such as using a cup or a comb). Simple techniques such as the localisation of subjective pain and fatigue accompanied by palpation of the area of discomfort can also be used. Mirror dystonia consists of dystonic postures and movements of the dominant hand while writing or performing other tasks with the non-dominant hand. We present a series of six patients who were successfully injected with BTX using mirror dystonia as an additional tool for muscle evaluation.

We carried out a retrospective review of the case records of consecutive patients with writing dystonia (writing tremor) who had been injected with BTX type A (Botox®, Allergan Pharmaceuticals, Irvine, California, USA) between November 2000 and October 2002 at our movement disorders clinic. Our study was limited to patients with writing dysfunction who displayed mirror dystonia while writing with their non-dominant hand. We specifically examined patients for mirror dystonia by asking them to write yok with their non-dominant hand while resting the dominant hand on the ulnar side of the forearm (unaware of our focus on the detection of mirror dystonia of the resting limb). Patients were injected under EMG guidance, using an Allergan® EMG needle. We recorded the muscles injected and the dose each muscle received. Peak effect was defined as the maximum benefit obtained from the injection. It was rated on a 0 to 3 global impression scale (0 = no effect; 1 = mild improvement; 2 = moderate improvement; 3 = marked improvement). The presence and severity of adverse events was also recorded. We also looked at the concordance between observation of the dominant limb in the action of writing and

Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction

The successful application of botulinum toxin (BTX) injections in the treatment of focal hand dystonia is largely dependent on careful evaluation and selection of muscles to be injected. It has been suggested that patients should be examined for abnormal postures at rest and while carrying out the affected task in question as well as other tasks (such as using a cup or a comb). Simple techniques such as the localisation of subjective pain and fatigue accompanied by palpation of the area of discomfort can also be used. Mirror dystonia consists of dystonic postures and movements of the dominant hand while writing or performing other tasks with the non-dominant hand. We present a series of six patients who were successfully injected with BTX using mirror dystonia as an additional tool for muscle evaluation.

We carried out a retrospective review of the case records of consecutive patients with writing dystonia (writing tremor) who had been injected with BTX type A (Botox®, Allergan Pharmaceuticals, Irvine, California, USA) between November 2000 and October 2002 at our movement disorders clinic. Our study was limited to patients with writing dysfunction who displayed mirror dystonia while writing with their non-dominant hand. We specifically examined patients for mirror dystonia by asking them to write yok with their non-dominant hand while resting the dominant hand on the ulnar side of the forearm (unaware of our focus on the detection of mirror dystonia of the resting limb). Patients were injected under EMG guidance, using an Allergan® EMG needle. We recorded the muscles injected and the dose each muscle received. Peak effect was defined as the maximum benefit obtained from the injection. It was rated on a 0 to 3 global impression scale (0 = no effect; 1 = mild improvement; 2 = moderate improvement; 3 = marked improvement). The presence and severity of adverse events was also recorded. We also looked at the concordance between observation of the dominant limb in the action of writing and

Figure 1 Cerebral white matter small vessel showing necrosis and perivascular microgliosis following occlusion by thrombus.
observation of the mirror dystonia movements of the same limb while writing with the non-dominant hand. The formulation and preparation of BTX was carried out using standard methods. Overviews of the demographic, clinical, and treatment variables are presented in table 1. We identified six patients with writing dysfunction (M/F:1/5, mean age 46 years (range 30 to 75), mean duration of disease 7.16 years (range 2 to 13)). Four patients (cases 1, 2, 3, and 6) had writer’s cramp and two (cases 3 and 4) had features overlapping writing tremor with writer’s cramp. Three patients reported marked (cases 1, 2, and 5), two moderate (cases 3 and 4), and one mild improvement (cases 6). We further identified two subgroups: four patients where mirror dystonia consisted of any combination of extension/abduction of the thumb, fingers, and wrist (subgroup A: cases 2, 3, 4, and 5) and two patients where mirror dystonia consisted of hyperflexion of wrist or thumb and fingers (subgroup B: cases 1 and 6). In subgroup A two patients experienced marked improvement and two had moderate improvement following injections. Two of these four patients did not show mirror dystonia movements when seen 15–17 weeks later at the time they were due for repeat injections. In subgroup B one patient experienced marked improvement and one mild improvement. None of our patients had evidence of mirror dystonia in the non-dominant hand when writing with the dominant hand. Regarding adverse events, transient weakness was experienced by four patients (for one to four weeks). No other adverse events were reported.

Concordance in the action of writing and observation of the mirror dystonia movements in the same limb was found in four patients. In three there was enrichment of the observation in that additional muscles could be shown to be active. The two discordant patients had writing tremor with no overt deviation noted when the dominant hand wrote.

The importance of recognition of mirror dystonia in patients with writing dysfunction has been previously highlighted by Jedynak et al. They reported that 29 of 65 patients with writer’s cramp had evidence of mirror dystonia and suggested that mirror dystonia may be useful in muscle selection (it may help in the differentiation between primary and compensatory movements). Borgohain et al also reported on the subject; however, that work has only been published in abstract form. The investigators proposed that mirror dystonia used as a guide for muscle selection for BTX injections may reduce the difference in outcome between extensor and flexor writer’s cramp and suggested that mirror dystonia was a superior method for muscle selection compared with compensatory movements.

Although the mechanism of mirror dystonia remains unclear it has been suggested that it is likely to be related to the metabolic abnormalities shown to involve the primary sensorimotor and supplementary motor cortices in patients with focal hand dystonia. Magnetic cortical stimulation has confirmed that corticocortical inhibition is reduced over both hemispheres. Jedynak et al suggested that mirror dystonia is the consequence of abnormal cortical inhibition and decreased selectivity of muscle patterns for highly skilled manual tasks.

We conclude that analysis of the pattern of dystonic posturing displayed in mirror dystonia when examining patients with writing dysfunction is a useful guide for selection of muscles to be injected with BTX. A prospective trial of BTX injections in muscles selected through analysis of mirror dystonia could provide further information about the therapeutic results of this method.

Table 1: Demographic variables, clinical features, and response to botulinum toxin treatment in our series of patients with writing dysfunction associated with mirror dystonia

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age</th>
<th>Duration</th>
<th>Type</th>
<th>Mirror dystonia</th>
<th>Muscles selected (dose)</th>
<th>Benefit</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>75</td>
<td>13 years</td>
<td>WC</td>
<td>Flexion of thumb and index finger</td>
<td>R FPL 12.5 U; R FDS 12.5 U</td>
<td>Marked</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>42</td>
<td>8 years</td>
<td>WC</td>
<td>Dorsiextension of thumb, index finger and wrist</td>
<td>R EPL 7.5 U</td>
<td>Marked</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>48</td>
<td>3 years</td>
<td>WT</td>
<td>Dorsiextension of fingers (not thumb) and wrist</td>
<td>R ECU 10 U; R EDC 10 U; R FDU 10 U (*)</td>
<td>Moderate</td>
<td>Transient (one month) weakness of extension of 2nd, 3rd, and 4th digits</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>38</td>
<td>2 years</td>
<td>WT</td>
<td>Hyperextension of the thumb</td>
<td>R APL 10 U</td>
<td>Moderate</td>
<td>Transient (one week) weakness of dorsiextension of the wrist</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>30</td>
<td>11 years</td>
<td>WC</td>
<td>Dorsiextension of index finger</td>
<td>R EIP 10 U</td>
<td>Marked</td>
<td>Transient (2 weeks) weakness of dorsiextension of finger (and milder weakness of extension of the thumb)</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>43</td>
<td>6 years</td>
<td>WC</td>
<td>Flexion of wrist and fingers</td>
<td>R FCR 12.5 U; R FCU 12.5 U</td>
<td>Mild</td>
<td>Weakness lifting objects</td>
</tr>
</tbody>
</table>

*Patient injected in FCU owing to discomfort in the volar aspect of the forearm

AFL, abductor pollicis longus; ECR, extensor carpi radialis; ECU, extensor carpi ulnaris; EDC, extensor digitorum communis; EIP, extensor indicis proprius; EPL, extensor pollicis longus; FCR, flexor carpi radialis; FCU, flexor carpi ulnaris; FDS, flexor digitorum superficialis; FPL, flexor pollicis longus; L, left; R, right; WR, writer’s cramp, WT, writing tremor.

Acknowledgements

This work was presented in part at the American Academy of Neurology 59th Annual Meeting in Honolulu, Hawaii, 31 March to 4 April 2003.

C Singer, S Papapetropoulos
Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA

L Vela
Fundación Hospital Alcalón, Alcorcón, Madrid, Spain

Correspondence to: Dr Carlos Singer, Associate Professor of Neurology, University of Miami, School of Medicine, 1501 NW 9th Avenue, Miami, FL 33136, USA; csinger@med.miami.edu
doi: 10.1136/jnnp.2004.062265

Competing interests: none declared

References

Drug induced pseudolymphoma secondary to ethosuximide

Ethosuximide is an antiepileptic succinimide, widely used in the treatment of absence seizures. Haemopoietic complications associated with the administration of this drug have included leucopenia, agranulocytosis, pancytopenia with or without bone marrow suppression, and eosinophilia. We report a patient with pseudolymphoma induced by ethosuximide, a complication never reported previously.

Case report

A 12 year old boy presented with a two month history of fever, weight loss (3 kg), and painful swellings on the neck, axillae, and inguinal regions. The patient had been on ethosuximide for three months for childhood absence epilepsy. It was being given at a dose of 30 mg/kg/day, in three divided doses, and the seizures had been under reasonable control.

Physical examination on presentation revealed enlarged lymph nodes on both sides of the neck, axillae, and inguinal regions. All the nodes were non-tender, firm, measuring 1 to 2 cm in diameter, and freely mobile. The liver and spleen were not palpable and all other systems were normal. A full blood count revealed a leucopenia of 3.6 x 10^9 /l (48% neutrophils, 3% eosinophils, 40% lymphocytes, and 9% monocytes) and a decreased platelet count of 119.0 x 10^9 /l. Studies for serological markers revealed an acute or chronic infection with cytomegalovirus, Epstein–Barr virus, herpes simplex virus, or toxoplasmosis.

An excisional biopsy of a 2 cm cervical node was done. Frozen section diagnosis was lymphoma, but leucocyte phenotyping shows heterogeneous cell population typical of lymphoid hyperplasia. Permanent sections showed a diffuse polymorphic lymphoid hyperplasia with effacement of the normal architecture; there was an admixture of lymphoid cells, including small and large lymphocytes and plasma cells (fig 1). Leucocyte phenotyping, using the ABC immunohistochemical method, showed heterogeneous T cell and B cell populations: T cell subsets included CD4+CD8+ and CD4+. B lymphocyte markers included CD20.

One day after ethosuximide discontinuation the fever disappeared. The lymph nodes were noticed to have decreased in size on the second week and completely regressed on the end of the second month. The leucocyte and platelet counts normalised after two weeks of ethosuximide withdrawal. Positive rechallenge resulted in drug induced fever and enlargement of the lymph nodes after one week of ethosuximide administration.

Comment

Lymphadenopathy has been recognised as a complication of drug treatment, particularly with antiepileptic drugs, since the first report of phenytoin-induced pseudolymphoma in 1940. Since then, this idiiosyncratic reaction has also been described with carbamazepine, lamotrigine, nifedipine, thioridazine, atenolol, amiodarone, hydralazine, mexiteline, penicillamine, captopril,enalapril, and methotrexate. Most of these are associated with cutaneous pseudolymphomas, but the antiepileptic drugs are more likely to precipitate cervical lymphadenopathy.

Pathologically, the term “pseudolymphoma” has been used to describe lymphoid cell proliferation with effacement of nodal architecture, so that there is a false appearance suggestive of malignancy. Although the precise pathogenesis of this drug reaction is unknown, pseudolymphoma may develop as a hypersensitivity reaction when a drug or one of its structural ligands acts as an antigen, triggering an immune reaction. Alternatively, the drug in question may promote a dysregulated immune response to another drug or non-pharmacological antigen.

Ethosuximide is widely used in the treatment of absence seizures. On the basis of more than a decade of studies on its cellular effects, the mechanisms of action are thought to include blockade of the low threshold T-type Ca^2+ current and a reduction in both the non-inactivating Na^+ current and the Ca^2+ activated K^+ current in thalamic and cortical neurones.

The most common dose related side effects are gastrointestinal complaints (nausea, vomiting, and anorexia) and central nervous system (CNS) effects (drowsiness, lethargy, euphoria, dizziness, headache, and hiccup). Some tolerance to these effects develops. Parkinson-like symptoms are also photophobia have been also reported. Urticaria and other skin reactions, including Stevens–Johnson syndrome, as well as systemic lupus erythematosus, eosinophilia, leucopenia, thrombocytopenia, pancytopenia, hepatic dysfunction, and aplastic anaemia, also have been attributed to ethosuximide.

In this case, the disappearance of lymphadenopathy with withdrawal of the drug, and its prompt reappearance when the drug was reintroduced, suggests a strong cause–effect association between ethosuximide and lymphadenopathy. To our knowledge, this is the first case report of ethosuximide induced pseudolymphoma and the second to report lymphadenopathy as an adverse effect of ethosuximide.

M R Masruha, C M Marques, L C P Vilanova
Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil

M T de Seixas Alves
Department of Pathology, Federal University of São Paulo

M F P Peres
Research and Teaching Institute, Albert Einstein Hospital, São Paulo

M G Rodrigues
Department of Paediatrics, Federal University of Esprito Santo, Espirito Santo, Brazil

Correspondence to: Dr Marcelo Rodrigues Masruha, Division of Child Neurology, Department of Neurology and Neursurgery, Botucatu Street 729, Federal University of São Paulo, São Paulo 04023-9000, Brazil; mmarsruha@ig.com.br

doi: 10.1136/jnnp.2005.064923

Competing interests: none declared

References


2 Cooper R, Burrows RGR. Treatment of epilepsy with sodium diphenylhydantoin. Lancet 1940;i, 490–2.


BOOK REVIEW

Imitators of Epilepsy, Second Edition


This 300 page hardcover work encompasses four sections: one on general considerations relevant to the topic with specific focus to epileptic versus non-epileptic diagnostic dilemmas; the second section presents different types of non-epileptic spells according to age of presentation; the third section describes other disorders that resemble epileptic seizures such as migraine, vestibular problems, movement disorders, hyponerelexia, and startle disorders; and the fourth section focuses on encephalopathies, neuro-endo-crine, metabolic and toxic conditions imitating epilepsy. Parasonias, sleep disorders and narcolepsy as well cerebral vascular imitators of epilepsy are also well described. The last section is relevant to psychological psychiatric imitators of epilepsy such as hyperventilation syndrome, psychogenic non-epileptic seizures, and panic attacks. Most chapters contain a review of the basic definitions and physiology of the respective differential diagnoses imitating epilepsy followed by the clinical characteristics and case vignettes. Some authors of this co-authored work provide a personal perspective regarding diagnosis and treatment. This book is of particular interest to any clinician working with epilepsy patients as it is to medical students on one side and general neurologists and specialised epileptologists on the other side. The fact that imitators of epilepsy are frequently encountered in non-neurological populations or patients presenting outside neurological services makes this book a useful addition to libraries of non-neurologists as well.

P A J M Boon
Drug induced pseudolymphoma secondary to ethosuximide

M R Masruha, C M Marques, L C P Vilanova, M T de Seixas Alves, M F P Peres and M G Rodrigues

J Neurol Neurosurg Psychiatry 2005 76: 1610
doi: 10.1136/jnnp.2005.064923

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/11/1610.1

These include:

References
This article cites 3 articles, 0 of which you can access for free at:
http://jnnp.bmj.com/content/76/11/1610.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/